0000950103-17-004144.txt : 20170502 0000950103-17-004144.hdr.sgml : 20170502 20170502123430 ACCESSION NUMBER: 0000950103-17-004144 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170502 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170502 DATE AS OF CHANGE: 20170502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37896 FILM NUMBER: 17803915 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp75782_8k.htm FORM 8-K

  
  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549
_______________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): May 2, 2017
 
SHIRE PLC
(Exact name of registrant as specified in its charter)
 
Jersey, Channel Islands 0-29630 98-0601486
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
     

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland
(Address of principal executive offices)

   
Registrant’s telephone number, including area code:     +353 1 429 7700
 
(Former name or former address, if changed since last report)
 
_______________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

Item 8.01. Other Events

 

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits. The following exhibit is filed herewith:

 

99.1       Press Release dated May 2, 2017

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Shire plc  
         
  By:  /s/ W R Mordan  
    Name:  Bill Mordan  
    Title: Company Secretary  

 

 

Date: May 2, 2017

 

 

EXHIBIT INDEX

 

Exhibit No. 

  

Description 

   
99.1   Press Release dated May 2, 2017

 

 

 

 

 

 EX-99.1 2 dp75782_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Press Release SL_rgb_lo_blue_pms3005 release.jpg 
www.shire.com  

 

 

 

Total Voting Rights

 

May 2, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”) Disclosure Guidance and Transparency Rules, notifies the market of the following:

 

As at April 30, 2017, the Company’s issued ordinary share capital comprised 907,120,639 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.

 

Therefore, the total number of voting rights in the Company is 907,120,639. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Sarah Rixon
Company Secretarial Assistant

 

 

 

For further information please contact:

 

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com   +1 617 949 9083

 

 

 

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com

 

 

 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

 

 

 GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg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